MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 03-14-2026
Ultragenyx Pharmaceutical Total Shareholders Equity 2011-2026 | RARE
Annual Total Shareholders Equity Ultragenyx Pharmaceutical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -80 M | 255 M | 275 M | 352 M | 923 M | 1.15 B | 654 M | 609 M | 383 M | 474 M | 531 M | 185 M | -74.8 M | -27 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 B | -80 M | 401 M |
Quarterly Total Shareholders Equity Ultragenyx Pharmaceutical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.16 M | 151 M | 144 M | 255 M | 347 M | 432 M | 140 M | 275 M | 31.7 M | 129 M | 220 M | 352 M | 469 M | 678 M | 796 M | 923 M | 934 M | 972 M | 1.05 B | 1.15 B | 666 M | 696 M | 609 M | 654 M | 727 M | 820 M | 887 M | 609 M | 609 M | 609 M | 609 M | 383 M | 383 M | 383 M | 383 M | 474 M | 474 M | 474 M | 474 M | 531 M | 531 M | 531 M | 531 M | 185 M | 185 M | 185 M | 185 M | -74.8 M | -74.8 M | -74.8 M | -74.8 M | -27 M | - | - | - | -7.96 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.15 B | -74.8 M | 433 M |
Total Shareholders Equity of other stocks in the Biotechnology industry
| Issuer | Total Shareholders Equity | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
621 M | - | 2.43 % | $ 254 M |  Germany |
 |
Heron Therapeutics
HRTX
|
14.3 M | $ 0.79 | 1.9 % | $ 132 M |  USA |
 |
Altimmune
ALT
|
225 M | $ 3.44 | 2.99 % | $ 303 M | USA |
 |
I-Mab
IMAB
|
1.72 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
-16.2 M | - | 2.54 % | $ 160 B |  France |
 |
Ascendis Pharma A/S
ASND
|
884 M | $ 218.03 | -1.74 % | $ 5 B |  Danmark |
 |
Biophytis SA
BPTS
|
2.27 M | - | -13.47 % | $ 169 M | France |
 |
Midatech Pharma plc
MTP
|
6.72 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Applied Genetic Technologies Corporation
AGTC
|
29.5 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
382 M | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
5.47 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
-158 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
176 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
54.4 M | - | 10.36 % | $ 9.8 M | USA |
 |
Acasti Pharma
ACST
|
66.6 M | - | 4.01 % | $ 150 M |  Canada |
 |
Incyte Corporation
INCY
|
5.17 B | $ 90.43 | -0.21 % | $ 17.7 B | USA |
 |
Inovio Pharmaceuticals
INO
|
117 M | $ 1.54 | -2.41 % | $ 34.1 M | USA |
 |
Avenue Therapeutics
ATXI
|
2.8 M | - | -52.27 % | $ 4.45 M | USA |
 |
Adverum Biotechnologies
ADVM
|
70.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
-16.8 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
-24.4 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-1.1 M | - | - | $ 7.46 M |  Israel |
 |
Cullinan Management
CGEM
|
409 M | $ 13.57 | 7.1 % | $ 818 M | USA |
 |
Atreca
BCEL
|
78.4 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
188 M | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.36 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Inventiva S.A.
IVA
|
111 M | $ 6.07 | 4.97 % | $ 138 M | France |
 |
Calithera Biosciences
CALA
|
8.38 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
57.1 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
286 M | - | - | $ 3.74 B | USA |
 |
Bellerophon Therapeutics
BLPH
|
2.53 M | - | -74.18 % | $ 955 K | USA |
 |
KalVista Pharmaceuticals
KALV
|
95.4 M | $ 16.82 | -1.06 % | $ 835 M | Britain |
 |
Checkpoint Therapeutics
CKPT
|
-12.6 M | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
-279 M | - | -7.23 % | $ 13 M | USA |
 |
Kamada Ltd.
KMDA
|
179 M | $ 8.27 | 0.24 % | $ 260 M | Israel |
 |
Aeglea BioTherapeutics
AGLE
|
715 M | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
688 M | - | - | $ 867 M | Germany |
 |
Compugen Ltd.
CGEN
|
103 M | $ 2.13 | 1.67 % | $ 199 M | Israel |
 |
Karyopharm Therapeutics
KPTI
|
-186 M | $ 7.11 | -6.82 % | $ 866 K | USA |
 |
Denali Therapeutics
DNLI
|
1.23 B | $ 20.99 | 4.07 % | $ 3.45 B | USA |
 |
Keros Therapeutics
KROS
|
303 M | $ 11.16 | 1.82 % | $ 415 M | USA |
 |
Akero Therapeutics
AKRO
|
750 M | - | - | $ 3.67 B | USA |
 |
Arbutus Biopharma Corporation
ABUS
|
106 M | $ 4.35 | 2.48 % | $ 722 M | Canada |
 |
Akouos
AKUS
|
234 M | - | 0.23 % | $ 488 M | USA |
 |
AIkido Pharma
AIKI
|
39.9 M | - | 1.93 % | $ 17.4 M | USA |
 |
Cyclacel Pharmaceuticals
CYCC
|
-2.17 M | - | -5.98 % | $ 34.1 M | USA |